Raptor plans to advance development of brain disorder drug
Raptor Pharmaceutical Corp said it plans to advance development of its brain disorder drug to a registration study, despite it failing to show statistical significance in a trial.
The drug, RP103, is being evaluated in patients with Huntington’s Disease, a type of neurodegenerative genetic disorder that affects muscle coordination and leads to mental decline and behavioral symptoms.
The drug showed a slowing rate in total motor score, compared with a placebo, according to data from the 36-month larger study.
Though not statistically significant, the 25 percent treatment effect in the motor score rate in patients treated with RP103 is regarded as “clinically meaningfulâ€, Raptor said on Thursday.
Total motor score is a rating system to quantify the severity of Huntington’s Disease.
There is no currently approved drug that slows disease progression, the company said.
Up to Wednesday’s close of $5.60, the company’s shares had fallen nearly 47 percent this year.
(Reporting by Shailesh Kuber and Rosmi Shaji in Bengaluru; Editing by Sriraj Kalluvila)